MRMD — Marimed Share Price
- $100.10m
- $153.44m
- $148.60m
- 40
- 87
- 39
- 55
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.11 | ||
Price to Tang. Book | 1.63 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0.67 | ||
EV to EBITDA | 11.68 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 2.39% | ||
Return on Equity | -17.14% | ||
Operating Margin | 2.66% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 45.6 | 50.9 | 121.46 | 134.01 | 148.6 | 157.35 | 195.85 | 65.82% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | +189.99 | +91.65 | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
MariMed Inc. is a multi-state cannabis operator in the United States. The Company develops, owns, and manages seed to sale regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. Its products include whole flowers, pre-rolled flowers, vape cartridges, concentrates, and edibles. The Company’s Natures Heritage brand is a premium brand of cannabis flower and concentrates. Its Bettys Eddies brand is a cannabis supplement and nutrient-infused fruit chew that delivers better sleep, pain relief, stress relief, and more. Its Bubbys Baked brand is a soft and chewy baked goods and a hot chocolate mix. Its Vibations brand is a cannabis-infused hydrating drink mix for discrete. The Company’s Kalm Fusion and K Fusion are chewable cannabis-infused mint tablets and InHouse is a brand of flower, vapes, and edibles. The Company’s Community Wellness & Compassionate Care Center, Inc. (Medleaf) is located in Prince George's County, Maryland.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 25th, 2011
- Public Since
- May 4th, 2012
- No. of Shareholders
- 735
- No. of Employees
- 643
- Sector
- Food & Drug Retailing
- Industry
- Consumer Defensives
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 375,465,266
- Address
- 10 OCEANA WAY, 2ND FLOOR, NORWOOD, 02062
- Web
- https://ir.marimedinc.com/
- Phone
- +1 7812770007
- Auditors
- M&K CPAS PLLC
Upcoming Events for MRMD
Q1 2024 MariMed Inc Earnings Call
Marimed Inc Annual Shareholders Meeting
Q2 2024 MariMed Inc Earnings Release
Similar to MRMD
American Green
Pink Sheets on Nasdaq
Bit Brother
Pink Sheets on Nasdaq
Blue Gem Enterprise
Pink Sheets on Nasdaq
Blum Holdings
Pink Sheets on Nasdaq
Can B
Pink Sheets on Nasdaq
FAQ
As of Today at 19:13 UTC, shares in Marimed are trading at $0.27. This share price information is delayed by 15 minutes.
Shares in Marimed last closed at $0.27 and the price had moved by -32.34% over the past 365 days. In terms of relative price strength the Marimed share price has underperformed the S&P500 Index by -41.56% over the past year.
The overall consensus recommendation for Marimed is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Marimed does not currently pay a dividend.
Marimed does not currently pay a dividend.
Marimed does not currently pay a dividend.
To buy shares in Marimed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.27, shares in Marimed had a market capitalisation of $100.10m.
Here are the trading details for Marimed:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: MRMD
Based on an overall assessment of its quality, value and momentum Marimed is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Marimed is $0.50. That is 87.55% above the last closing price of $0.27.
Analysts covering Marimed currently have a consensus Earnings Per Share (EPS) forecast of -$0.03 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Marimed. Over the past six months, its share price has underperformed the S&P500 Index by -30.49%.
As of the last closing price of $0.27, shares in Marimed were trading -18.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Marimed PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.27.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Marimed's directors